This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Training and Resources

KEYTRUDA® (pembrolizumab) in the adjuvant treatment of melanoma

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

 

KEYTRUDA® (pembrolizumab) in advanced melanoma

KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

 

Patient education and support materials

 

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-OOC-00300 | Date of Preparation: December 2020